EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan
New indication concerns the treatment of unresectable or metastatic HER2-low breast cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas
Different molecular subtypes of appendiceal adenocarcinomas have distinct clinical and biological behaviours that may be useful in guiding therapeutic decision
Reduction Not Only in Recurrences, but Also in Mortality, Observed for Exemestane Plus Ovarian Function Suppression in Premenopausal Women with Hormone Receptor Positive EBC
Findings from a combined analysis of SOFT-TEXT after a median follow-up of 13 years
Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory DLBCL
Glofitamab induces durable complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma
FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC
FDA also approved the QIAGEN therascreen KRAS RGQ PCR kit (tissue) and the Agilent Resolution ctDx FIRST Assay (plasma) as companion diagnostics
FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
Evidence for efficacy is based on the results from the Study ML39345
Longer PFS in Patients with Advanced Melanoma Treated with TILs than among Those Who Received Ipilimumab
Findings from a randomised phase III study
One in Five of Older Patients with EBC Treated in a Prospective Cohort Received Low Chemotherapy Relative Dose Intensity and Had Inferior Survival
Findings from a prespecified secondary analysis of the HOPE study
Pembrolizumab Improves Survival in Patients from Asia with Previously Treated Advanced Hepatocellular Carcinoma
Findings from the KEYNOTE-394 study
FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible IDH1 Mutation
It also approved the Abbott RealTime IDH1 Assay to select patients
Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and Delays Development of New Brain Metastases in Patients with HER2-Positive MBC
Findings from an updated exploratory analysis of the HER2CLIMB study
Two-Step Approach Might Be An Alternative to Standard Three-Step Approach of the WHO Analgesic Ladder for Cancer Pain Management
Findings from an international randomised parallel group study